Switch to:
Also traded in: UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 0.91
ICLR's Cash to Debt is ranked lower than
65% of the 197 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.06 vs. ICLR: 0.91 )
Ranked among companies with meaningful Cash to Debt only.
ICLR' s Cash to Debt Range Over the Past 10 Years
Min: 0.85  Med: 50.70 Max: No Debt
Current: 0.91
Equity to Asset 0.48
ICLR's Equity to Asset is ranked lower than
68% of the 183 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.61 vs. ICLR: 0.48 )
Ranked among companies with meaningful Equity to Asset only.
ICLR' s Equity to Asset Range Over the Past 10 Years
Min: 0.48  Med: 0.65 Max: 0.77
Current: 0.48
0.48
0.77
Interest Coverage 146.58
ICLR's Interest Coverage is ranked lower than
52% of the 93 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 166.12 vs. ICLR: 146.58 )
Ranked among companies with meaningful Interest Coverage only.
ICLR' s Interest Coverage Range Over the Past 10 Years
Min: 17.93  Med: 65.30 Max: 382.53
Current: 146.58
17.93
382.53
F-Score: 7
Z-Score: 4.21
M-Score: -2.68
WACC vs ROIC
6.45%
26.95%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 16.51
ICLR's Operating margin (%) is ranked higher than
88% of the 187 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.66 vs. ICLR: 16.51 )
Ranked among companies with meaningful Operating margin (%) only.
ICLR' s Operating margin (%) Range Over the Past 10 Years
Min: 3.11  Med: 10.37 Max: 13.46
Current: 16.51
3.11
13.46
Net-margin (%) 14.16
ICLR's Net-margin (%) is ranked higher than
88% of the 187 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.98 vs. ICLR: 14.16 )
Ranked among companies with meaningful Net-margin (%) only.
ICLR' s Net-margin (%) Range Over the Past 10 Years
Min: 2.42  Med: 8.64 Max: 11.47
Current: 14.16
2.42
11.47
ROE (%) 22.82
ICLR's ROE (%) is ranked higher than
94% of the 180 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -6.39 vs. ICLR: 22.82 )
Ranked among companies with meaningful ROE (%) only.
ICLR' s ROE (%) Range Over the Past 10 Years
Min: 3.39  Med: 14.16 Max: 18.54
Current: 22.82
3.39
18.54
ROA (%) 13.56
ICLR's ROA (%) is ranked higher than
94% of the 197 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -4.60 vs. ICLR: 13.56 )
Ranked among companies with meaningful ROA (%) only.
ICLR' s ROA (%) Range Over the Past 10 Years
Min: 2.31  Med: 9.34 Max: 11.61
Current: 13.56
2.31
11.61
ROC (Joel Greenblatt) (%) 105.26
ICLR's ROC (Joel Greenblatt) (%) is ranked higher than
93% of the 194 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -3.03 vs. ICLR: 105.26 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
ICLR' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: 12.45  Med: 39.36 Max: 100.35
Current: 105.26
12.45
100.35
Revenue Growth (3Y)(%) 15.40
ICLR's Revenue Growth (3Y)(%) is ranked higher than
79% of the 118 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.70 vs. ICLR: 15.40 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
ICLR' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -14.6  Med: 10.35 Max: 54.5
Current: 15.4
-14.6
54.5
EBITDA Growth (3Y)(%) 52.70
ICLR's EBITDA Growth (3Y)(%) is ranked higher than
95% of the 99 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.90 vs. ICLR: 52.70 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
ICLR' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -0.95 Max: 52.7
Current: 52.7
0
52.7
EPS Growth (3Y)(%) 93.90
ICLR's EPS Growth (3Y)(%) is ranked higher than
95% of the 110 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.10 vs. ICLR: 93.90 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
ICLR' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -33.9  Med: 5.35 Max: 93.9
Current: 93.9
-33.9
93.9
» ICLR's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2014

ICLR Guru Trades in Q4 2014

Chuck Royce 210,200 sh (unchged)
Caxton Associates Sold Out
Ron Baron 1,469,024 sh (-3.07%)
Jim Simons 524,760 sh (-23.96%)
» More
Q1 2015

ICLR Guru Trades in Q1 2015

Jim Simons 528,260 sh (+0.67%)
Ron Baron 1,469,024 sh (unchged)
Chuck Royce 177,400 sh (-15.60%)
» More
Q2 2015

ICLR Guru Trades in Q2 2015

Jim Simons 539,200 sh (+2.07%)
Chuck Royce 156,600 sh (-11.72%)
Ron Baron 1,138,759 sh (-22.48%)
» More
Q3 2015

ICLR Guru Trades in Q3 2015

Ron Baron 1,138,759 sh (unchged)
Chuck Royce 150,700 sh (-3.77%)
Jim Simons 377,460 sh (-30.00%)
» More
» Details

Insider Trades

Latest Guru Trades with ICLR

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 18.80
ICLR's P/E(ttm) is ranked higher than
82% of the 85 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 29.20 vs. ICLR: 18.80 )
Ranked among companies with meaningful P/E(ttm) only.
ICLR' s P/E(ttm) Range Over the Past 10 Years
Min: 6.3  Med: 17.91 Max: 78.79
Current: 18.8
6.3
78.79
Forward P/E 12.72
ICLR's Forward P/E is ranked higher than
78% of the 63 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 18.32 vs. ICLR: 12.72 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 18.80
ICLR's PE(NRI) is ranked higher than
80% of the 86 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 29.80 vs. ICLR: 18.80 )
Ranked among companies with meaningful PE(NRI) only.
ICLR' s PE(NRI) Range Over the Past 10 Years
Min: 6.3  Med: 17.84 Max: 78.03
Current: 18.8
6.3
78.03
P/B 4.48
ICLR's P/B is ranked lower than
67% of the 177 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.84 vs. ICLR: 4.48 )
Ranked among companies with meaningful P/B only.
ICLR' s P/B Range Over the Past 10 Years
Min: 0.46  Med: 2.31 Max: 5.55
Current: 4.48
0.46
5.55
P/S 2.66
ICLR's P/S is ranked higher than
51% of the 178 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.78 vs. ICLR: 2.66 )
Ranked among companies with meaningful P/S only.
ICLR' s P/S Range Over the Past 10 Years
Min: 0.58  Med: 1.50 Max: 3.3
Current: 2.66
0.58
3.3
PFCF 21.51
ICLR's PFCF is ranked higher than
65% of the 68 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 25.57 vs. ICLR: 21.51 )
Ranked among companies with meaningful PFCF only.
ICLR' s PFCF Range Over the Past 10 Years
Min: 5.85  Med: 20.31 Max: 600.25
Current: 21.51
5.85
600.25
POCF 17.40
ICLR's POCF is ranked higher than
57% of the 88 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 20.31 vs. ICLR: 17.40 )
Ranked among companies with meaningful POCF only.
ICLR' s POCF Range Over the Past 10 Years
Min: 4.65  Med: 15.34 Max: 88.35
Current: 17.4
4.65
88.35
EV-to-EBIT 15.04
ICLR's EV-to-EBIT is ranked higher than
61% of the 101 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 21.06 vs. ICLR: 15.04 )
Ranked among companies with meaningful EV-to-EBIT only.
ICLR' s EV-to-EBIT Range Over the Past 10 Years
Min: 1.6  Med: 14.50 Max: 48
Current: 15.04
1.6
48
EV-to-EBITDA 12.34
ICLR's EV-to-EBITDA is ranked higher than
58% of the 105 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 14.38 vs. ICLR: 12.34 )
Ranked among companies with meaningful EV-to-EBITDA only.
ICLR' s EV-to-EBITDA Range Over the Past 10 Years
Min: 0.9  Med: 10.55 Max: 23.6
Current: 12.34
0.9
23.6
PEG 1.57
ICLR's PEG is ranked higher than
79% of the 42 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.69 vs. ICLR: 1.57 )
Ranked among companies with meaningful PEG only.
ICLR' s PEG Range Over the Past 10 Years
Min: 0.2  Med: 1.44 Max: 8.36
Current: 1.57
0.2
8.36
Shiller P/E 38.52
ICLR's Shiller P/E is ranked lower than
57% of the 30 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 36.62 vs. ICLR: 38.52 )
Ranked among companies with meaningful Shiller P/E only.
ICLR' s Shiller P/E Range Over the Past 10 Years
Min: 9.95  Med: 19.28 Max: 48.7
Current: 38.52
9.95
48.7
Current Ratio 1.12
ICLR's Current Ratio is ranked lower than
86% of the 191 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.68 vs. ICLR: 1.12 )
Ranked among companies with meaningful Current Ratio only.
ICLR' s Current Ratio Range Over the Past 10 Years
Min: 1.12  Med: 1.95 Max: 3.61
Current: 1.12
1.12
3.61
Quick Ratio 1.12
ICLR's Quick Ratio is ranked lower than
81% of the 191 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.41 vs. ICLR: 1.12 )
Ranked among companies with meaningful Quick Ratio only.
ICLR' s Quick Ratio Range Over the Past 10 Years
Min: 1.12  Med: 1.95 Max: 3.61
Current: 1.12
1.12
3.61
Days Sales Outstanding 90.35
ICLR's Days Sales Outstanding is ranked lower than
70% of the 155 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 65.71 vs. ICLR: 90.35 )
Ranked among companies with meaningful Days Sales Outstanding only.
ICLR' s Days Sales Outstanding Range Over the Past 10 Years
Min: 66.88  Med: 87.76 Max: 93.59
Current: 90.35
66.88
93.59
Days Payable 120.12
ICLR's Days Payable is ranked higher than
79% of the 149 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 52.88 vs. ICLR: 120.12 )
Ranked among companies with meaningful Days Payable only.
ICLR' s Days Payable Range Over the Past 10 Years
Min: 1.13  Med: 8.51 Max: 104.03
Current: 120.12
1.13
104.03

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 57.22
ICLR's Price/Net Current Asset Value is ranked lower than
94% of the 113 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.80 vs. ICLR: 57.22 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
ICLR' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 0.88  Med: 6.68 Max: 60.14
Current: 57.22
0.88
60.14
Price/Tangible Book 15.52
ICLR's Price/Tangible Book is ranked lower than
85% of the 156 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.14 vs. ICLR: 15.52 )
Ranked among companies with meaningful Price/Tangible Book only.
ICLR' s Price/Tangible Book Range Over the Past 10 Years
Min: 0.64  Med: 3.24 Max: 16.31
Current: 15.52
0.64
16.31
Price/Projected FCF 1.82
ICLR's Price/Projected FCF is ranked higher than
56% of the 66 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.00 vs. ICLR: 1.82 )
Ranked among companies with meaningful Price/Projected FCF only.
ICLR' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.52  Med: 1.72 Max: 6.7
Current: 1.82
0.52
6.7
Price/Median PS Value 1.77
ICLR's Price/Median PS Value is ranked lower than
90% of the 157 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.91 vs. ICLR: 1.77 )
Ranked among companies with meaningful Price/Median PS Value only.
ICLR' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.38  Med: 0.94 Max: 1.91
Current: 1.77
0.38
1.91
Price/Peter Lynch Fair Value 0.75
ICLR's Price/Peter Lynch Fair Value is ranked higher than
93% of the 28 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.11 vs. ICLR: 0.75 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
ICLR' s Price/Peter Lynch Fair Value Range Over the Past 10 Years
Min: 0.2  Med: 1.37 Max: 3.23
Current: 0.75
0.2
3.23
Price/Graham Number 3.60
ICLR's Price/Graham Number is ranked lower than
66% of the 94 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.37 vs. ICLR: 3.60 )
Ranked among companies with meaningful Price/Graham Number only.
ICLR' s Price/Graham Number Range Over the Past 10 Years
Min: 0.42  Med: 1.56 Max: 3.78
Current: 3.6
0.42
3.78
Earnings Yield (Greenblatt) (%) 6.60
ICLR's Earnings Yield (Greenblatt) (%) is ranked higher than
79% of the 189 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.10 vs. ICLR: 6.60 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
ICLR' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 2.1  Med: 6.90 Max: 63.7
Current: 6.6
2.1
63.7
Forward Rate of Return (Yacktman) (%) 30.94
ICLR's Forward Rate of Return (Yacktman) (%) is ranked higher than
89% of the 57 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 11.03 vs. ICLR: 30.94 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
ICLR' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: -15  Med: 9.30 Max: 31.1
Current: 30.94
-15
31.1

More Statistics

Revenue(Mil) $1562
EPS $ 3.60
Beta0.61
Short Percentage of Float4.76%
52-Week Range $56.26 - 84.14
Shares Outstanding(Mil)57.23

Analyst Estimate

Dec15 Dec16 Dec17
Revenue(Mil) 1,582 1,718 1,848
EPS($) 3.97 4.69 5.31
EPS without NRI($) 3.97 4.69 5.31

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:LH, ALR, DGX, LIFE, ENZ » details
Traded in other countries:0NBW.UK,
Icon PLC was incorporated in 1990. The Company is a contract research organization that provides outsourced development services to the pharmaceutical, biotechnology, and medical device industries. The Company organized, operated and assessed its business in two segments, the clinical research segment and the central laboratory segment. The Clinical Research business specializes in the planning, management, execution and analysis of Phase I - IV clinical trials, ranging from small studies to complex, multinational projects. It also conduct various laboratory tests on the patient's blood, urine and other bodily fluids at appropriate intervals during the trial Specific clinical research services. The Company provides laboratory services through its central laboratory business, which includes the Company's central laboratories located in Dublin, New York, India, Singapore and China. The Company's areas of operation outside of Ireland include the United States, United Kingdom, France, Germany, Italy, Spain, The Netherlands, Sweden, Belgium, Turkey, Poland, Czech Republic, Lithuania, Latvia, Russia, Ukraine, Hungary, Israel, Romania, Canada, Mexico, Brazil, Colombia, Argentina, Chile, Peru, India, China, South Korea, Japan, Thailand, Taiwan, Singapore, The Philippines, Australia, New Zealand, and South Africa. The Company's principal competitors are Covance Inc., PAREXEL International Corporation, Pharmaceutical Product Development Inc., Quintiles Transnational Corporation, inVentiv Health , PRA and INC Research.
» More Articles for NAS:ICLR

Headlines

Articles On GuruFocus.com
Probable Gainers Of A European Market Bounce Back Jan 25 2015 
Meridian Funds Comments on Icon PLC Dec 17 2014 
Meridian Contrarian Fund 3Q 2014 Commentary Dec 17 2014 
Baron Funds Comments on ICON PLC Jun 10 2013 
Parexcel: Great Growth but a Tough Business Aug 17 2011 
Weekly Guru Bargains Highlights: SD, CREE, AMLN, ICLR, CVD Nov 07 2010 

More From Other Websites
ICON Releases Flex Advantage to Enhance Patient Randomisation and Clinical Supply Management in... Jan 19 2016
The Zacks Analyst Blog Highlights: Aegean Marine Petroleum Network, Danaos, Tsakos Energy... Jan 13 2016
5 Smart PIIGS Stocks to Buy Now Jan 12 2016
Top-Notch Funds Buying Constellation, Northrop Grumman Jan 08 2016
ICON Plc breached its 50 day moving average in a Bearish Manner : January 8, 2016 Jan 08 2016
The Top 5 Mid Cap Healthcare Stocks for 2016 (COO, ICLR) Jan 07 2016
What's Your Stock's Price Target? Jan 05 2016
ICON Secures Investment Grade Credit Ratings Jan 05 2016
ICON Secures Investment Grade Credit Ratings Jan 05 2016
ICON Secures Investment Grade Credit Ratings Jan 05 2016
ICON Plc -- Moody's assigns first time Baa3 issuer rating to ICON Plc, stable outlook Jan 05 2016
ICON plc Announces Private Placement of US$350,000,000 of Senior Notes Dec 16 2015
ICON plc Announces Private Placement of US$350,000,000 of Senior Notes Dec 16 2015
ICON Accelerates Site Activation Timelines by up to 25% Dec 09 2015
ICON PLC Financials Dec 08 2015
ICON Acquires PMG Research Inc. Dec 07 2015
ICON Acquires PMG Research, Inc. Dec 07 2015
ICON Acquires PMG Research, Inc. Dec 07 2015
Is ICON plc – Ordinary Shares (ICLR) A Good Stock To Buy? Nov 30 2015
ICON Announces the Appointment of Dr. Steve Cutler to Board of Directors Nov 25 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK